Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 93.24% is in line with its 5-year average of 91.17%, near the high end of its 5-year range (0.00%–93.79%).
0.50% above its 12-month average of 92.77%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 93.79%.
GROSS MARGIN
93.24%
GROSS MARGIN AVG TTM
92.77%
GROSS MARGIN AVG 3Y
91.52%
GROSS MARGIN AVG 5Y
91.17%
GROSS MARGIN AVG 10Y
37.80%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.50%
CURRENT VS 3Y AVG
+1.88%
CURRENT VS 5Y AVG
+2.27%
CURRENT VS 10Y AVG
+146.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+125.33%
vs the sector median at left
Axsome Therapeutics, Inc.
Market Cap
$8.96B
Gross Margin
93.24%
TTM Avg
92.77%
3Y Avg
91.52%
5Y Avg
91.17%
Market Cap
$8.95B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$8.88B
Gross Margin
99.86%
TTM Avg
98.67%
3Y Avg
99.34%
5Y Avg
99.56%
Market Cap
$9.20B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$8.63B
Gross Margin
100.00%
TTM Avg
-161.83%
3Y Avg
-33.28%
5Y Avg
-5.52%
Market Cap
$8.61B
Gross Margin
101.98%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$8.39B
Gross Margin
14.38%
TTM Avg
17.24%
3Y Avg
38.82%
5Y Avg
59.22%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $8.96B | 93.24% | 92.77% | 91.52% | 91.17% |
| Bruker Corporation (BRKRP)vs › | $8.95B | 46.69% | 47.45% | 49.39% | 49.15% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.88B | 99.86% | 98.67% | 99.34% | 99.56% |
| Bruker Corporation (BRKR)vs › | $9.20B | 46.69% | 47.45% | 49.39% | 49.15% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.63B | 100.00% | -161.83% | -33.28% | -5.52% |
| Insulet Corp. (PODD)vs › | $9.31B | 71.08% | 70.71% | 67.87% | 67.39% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.61B | 101.98% | 100.00% | 100.00% | 100.00% |
| Vaxcyte, Inc. (PCVX)vs › | $9.50B | 0.00% | 0.00% | 0.00% | 0.00% |
| Oscar Health, Inc. (OSCR)vs › | $8.39B | 14.38% | 17.24% | 38.82% | 59.22% |
| Henry Schein, Inc. (HSIC)vs › | $9.62B | 30.31% | 29.43% | 29.32% | 29.12% |
Gross Margin
93.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 93.79% |
| 2026-03-31 | 92.30% |
| 2025-12-31 | 93.71% |
| 2025-09-30 | 93.03% |
| 2025-06-30 | 91.04% |
| 2025-03-31 | 91.94% |
| 2024-12-31 | 91.15% |
| 2024-09-30 | 91.95% |
| 2024-06-30 | 90.76% |
| 2024-03-31 | 91.60% |
| 2023-12-31 | 89.69% |
| 2023-09-30 | 88.70% |
| 2023-06-30 | 90.15% |
| 2023-03-31 | 92.01% |
| 2022-12-31 | 90.60% |
| 2022-09-30 | 88.58% |
| 2022-06-30 | 88.85% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
